Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results

08 May 2026, 18:01 by Doug Wharley · The Cerbat Gem

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.09, FiscalAI reports. The company had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.

Here are the key takeaways from Entrada Therapeutics’ conference call:

Favorable safety and tolerability at 6 mg/kg: no serious adverse events, mostly mild–moderate AEs (headache most common), normal kidney markers, and all eight Cohort 1 participants have moved into the open‑label period.
Treated participants showed a statistically significant and clinically meaningful improvement in Time To Rise (TTR) velocity versus placebo (mean change 0.08 rises/sec, ~3.5× the MCID), with benefits across most patients despite the small sample size.
Pediatric PK was ~50% lower than in healthy adult volunteers and adult NHPs, producing modest exon skipping (~2.3% above baseline) and low dystrophin at biopsy (≈2.3% then ~6% at day 127), creating exposure and dosing uncertainty that must be addressed.
Updated modeling using juvenile NHP data projects a dose‑dependent, potentially non‑linear increase in plasma AUC/exon skipping; management expects double‑digit dystrophin in Cohort 2 (12 mg/kg) and higher in Cohort 3, with Cohort 2 dosing underway and results due by year‑end 2026.
Pipeline and timing: Entrada highlights multiple near‑term catalysts (Cohort 1 open‑label and Cohort 2 readouts by year‑end 2026, ELEVATE‑45 Cohort 1 mid‑2026, partner DM1 data H2 2026) and a reported cash runway into the third quarter of 2027.

Entrada Therapeutics Price Performance

NASDAQ TRDA traded down $0.04 on Friday, hitting $6.82. 1,315,493 shares of the stock were exchanged, compared to its average volume of 275,857. Entrada Therapeutics has a 52-week low of $4.93 and a 52-week high of $16.45. The company has a market capitalization of $264.56 million, a price-to-earnings ratio of -1.97 and a beta of -0.09. The company’s 50-day moving average price is $12.82 and its two-hundred day moving average price is $10.90.

More Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

Positive Sentiment: Entrada reported positive topline results from Cohort 1 of its ELEVATE-44-201 study in Duchenne muscular dystrophy, including favorable safety and tolerability, no serious adverse events, and a statistically significant improvement in Time to Rise velocity versus placebo. Article Title
Positive Sentiment: The company said its cash, cash equivalents and marketable securities totaled about $255 million at quarter-end, with runway projected into Q3 2027, reducing near-term financing risk. Article Title
Neutral Sentiment: Entrada beat earnings expectations for the quarter, posting a loss of $0.95 per share versus consensus for a larger loss, but revenue came in well below estimates at $0.88 million. Article Title
Negative Sentiment: Despite the encouraging efficacy signal, the stock sold off sharply as traders weighed whether the early Duchenne data are strong enough to support the program’s valuation. Article Title
Negative Sentiment: Q1 collaboration revenue fell sharply year over year and net loss widened, reinforcing concerns that Entrada remains heavily dependent on clinical execution to justify the current valuation. Article Title

Insiders Place Their Bets

In other news, insider Natarajan Sethuraman sold 25,907 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.39, for a total transaction of $398,708.73. Following the transaction, the insider directly owned 216,317 shares in the company, valued at $3,329,118.63. The trade was a 10.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Nathan J. Dowden sold 15,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued at approximately $3,044,354.04. This represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 82,882 shares of company stock worth $1,169,103. Corporate insiders own 9.49% of the company’s stock.

Hedge Funds Weigh In On Entrada Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Alliancebernstein L.P. grew its holdings in shares of Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after acquiring an additional 1,620 shares in the last quarter. Great Lakes Advisors LLC grew its holdings in shares of Entrada Therapeutics by 5.5% during the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after acquiring an additional 2,239 shares in the last quarter. Quadrature Capital Ltd grew its holdings in shares of Entrada Therapeutics by 13.5% during the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after acquiring an additional 2,424 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Entrada Therapeutics by 3.6% during the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock valued at $505,000 after acquiring an additional 2,631 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 31.4% during the 4th quarter. Russell Investments Group Ltd. now owns 11,571 shares of the company’s stock valued at $119,000 after acquiring an additional 2,763 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on TRDA shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday. Roth Mkm set a $10.00 price objective on shares of Entrada Therapeutics in a research report on Friday. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Cantor Fitzgerald started coverage on shares of Entrada Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Check Out Our Latest Report on Entrada Therapeutics

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.